SCIENTURE HOLDINGS INC (SCNX)
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-10-30
$3.22-7.74%
Close 2026-10-30 · 1-day change
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-10-30
Research Workspace
Put SCNX beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Revenue growth above minimal guidance: Comparison needs review.
View ThesisManagement screens weak on margins, market reaction to earnings.
View ManagementThis stock is highly volatile — it swings about 3% on a typical day and fell roughly 86% in its worst 12-month stretch.
View RiskSCNX’s case rests on growing revenue from commercializing Arbli and REZENOPY. Q3 revenue was $1.22 million, up 256% sequentially. One quarter does not establish durable growth. The desk lacks a current valuation multiple and peer comparison. So the price’s reflection of that growth remains unclear. The next-quarter miss probability is 45%. A reverse split also flags pressure on SCNX’s financial position. The thesis is on watch because revenue growth needs review. The valuation read is provisional.
Trailing returns as of 2026-10-30. SCNX is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 1 analyst currently covering SCNX (as of Oct 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare SCNX with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| SCNX Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care (broad) — fair value, gap to price, and forward P/E.
Compare the value case
Put SCNX next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Expand revenue through commercial growth
Reported sequential revenue growth is a meaningful commercial-growth signal, though one quarter alone does not establish durability.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Threatens: Strengthen financial position and capital structure
Reverse split is a capital-structure warning and may signal pressure, though it does not alone break the thesis.
Advances: Commercialize Arbli and REZENOPY and expand the product portfolio
Distribution agreement supports commercialization of naloxone and broadens access to the product.
Advances: Commercialize Arbli and REZENOPY and expand the product portfolio
Company launch of its second FDA-approved commercial product advances portfolio commercialization.
